DrugPatentWatch Database Preview
Drugs in Development Information for Lucitanib
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for Lucitanib?
Lucitanib is an investigational drug.
There have been 8 clinical trials for Lucitanib.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2014.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, and Neoplasms. The leading clinical trial sponsors are Clovis Oncology, Inc., Servier, and Bristol-Myers Squibb.
There are twelve US patents protecting this investigational drug and ninety-eight international patents.
Summary for Lucitanib
| US Patents | 12 |
| International Patents | 98 |
| US Patent Applications | 22 |
| WIPO Patent Applications | 17 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2014-07-01) |
| Vendors | 35 |
Recent Clinical Trials for Lucitanib
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy | Bristol-Myers Squibb | Phase 1/Phase 2 |
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | Bristol-Myers Squibb | Phase 1/Phase 2 |
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | Clovis Oncology, Inc. | Phase 1/Phase 2 |
Clinical Trial Summary for Lucitanib
Top disease conditions for Lucitanib
Top clinical trial sponsors for Lucitanib
US Patents for Lucitanib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Lucitanib | Start Trial | Human anti-VEGFR-2/KDR antibodies | KADMON CORPORATION, LLC (New York, NY) | Start Trial |
| Lucitanib | Start Trial | Rho kinase inhibitors | KADMON CORPORATION, LLC (New York, NY) | Start Trial |
| Lucitanib | Start Trial | Rho kinase inhibitors | Kadmon Corporation, LLC (New York, NY) | Start Trial |
| Lucitanib | Start Trial | Human anti-VEGFR-2/KDR antibodies | Kadmon Corporation, LLC (New York, NY) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Lucitanib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Lucitanib | Canada | 2926386 | 2032-10-05 | Start Trial |
| Lucitanib | China | 105007939 | 2032-10-05 | Start Trial |
| Lucitanib | China | 109160950 | 2032-10-05 | Start Trial |
| Lucitanib | Eurasian Patent Organization | 032679 | 2032-10-05 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
